CompletedPhase 3ACTRN12608000248369

The role of Gabapentin in the treatment of refractory chronic dry cough.

The role of Gabapentin in the treatment of refractory chronic dry cough: A randomised double-blind placebo-controlled study.

Sponsor

Hunter New England Area Health Service

Enrollment

56 participants

Start Date

Oct 15, 2008

Study Type

Interventional

Conditions

chronic cough

Summary

looking at effectiveness of treating persistent cough with a medication

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 80 Yearss

Plain Language Summary

Simplified for easier understanding

This study is looking at the role of Gabapentin in the treatment of refractory chronic dry cough. It is open to both men and women, aged 18 to 80, who persistent non-productive cough of more than 8 weeks duration,. People with certain health conditions such as productive cough, may not be able to join. If you take part, the research team will explain what is involved and monitor your health throughout the study.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

300 mg of oral Neurontin once per day, then increased to 600mg/d for second day, then 900mg/d for third day upto maximum tolerable dose of 1800mg/day for ten weeks.

Locations(1)

NSW, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000248369